2 minute read
LES Israel Society News
Event Dedicated To Various Aspects Of The Medical Cannabis Industry
Advertisement
LES Israel held a successful event that was dedicated to various aspects of the Medical Cannabis Industry.
The event was held in Tel Aviv, on May 7, 2019, and attracted over 60 participants from a wide array of sectors. Among them, attorneys and patent attorneys from law and patent offices; directors in industrial companies (e.g.: CEOs, IP directors, Business Development directors, R&D directors, etc.); scientists and officers from academic institutes; office holders in government ministries; entrepreneurs, etc.
The event was titled: “The Medical Cannabis Industry—Navigate Between Legal/Regulatory Requirements And Business Opportunities.”
The event provided an opportunity to understand the scientific and medical backgrounds in general, and the resulted challenges in particular, which followed by some examples of unique industrial solutions, as well as the legal, regulatory and intellectual property aspects of this field.
A group of top tier presenters was assembled by Adv. Dalit Sagiv (LES Israel Secretary and board member) in order to cope with this ambitious goal.
Following a short presentation of LESI and LES Israel by Hananel Kvatinsky (LES Israel President and board member), the following presenters shared their knowledge and points of view:
• Dr. Gil Lewitus (PhD), Research Associate, The Laboratory of Cancer Biology and Cannabinoid Research, Technion—Israel Institute of Technology, “Medicalization of Medical Cannabis.”
• Ms. Ronit Bar-Gil, Educational Nurse, Syqe Medical Ltd., “Medical Cannabis–From Use to Accepted Treatment.”
• Ms. Miri Ogintz, Director of the Medical Cannabis Patient Support Program, Institute of Pain Medicine, Rambam Health Care Campus, contributed significantly to Ronit Bar-Gil's presentation.
• Dr. Roni Attali (PhD), VP Research and Compliance, GemmaCert, Ltd., “The Need for Cannabis Standards: The Next Step on the Path of Legalization.”
• Mr. Itai Rogel, Head of Business Development, Bazelet, Ltd., “Medical Cannabis—Israel & Beyond.”
• Mr. Itai Melchior, Director, Export Policy, Head of Inter-Ministerial Committee for the Export of Medicinal Cannabis, Foreign Trade Administration, Ministry of Economy, “From Medicalization to Export of Medicinal Cannabis.”
• Dr. Nadya Lisovoder (M.D.), CEO, MediCaNL Ltd., and Director of the Galilee Research Administration (Clinical Bio Research, operated by the Ministry for the Development of the Negev and Galilee), “Regulatory and Methodology Aspects of Clinical Studies and Drug Development in Medical Cannabis Products.”
• Dr. Daniella Atzmony (PhD, Advocate & Patent Attorney), Chief Innovation Strategy & IP Officer, Syqe Medical Ltd., “IPR Protection in Medical Cannabis.”
• Dr. Joe I. Wyse (PhD, Patent Attorney), Head of the Patent Department at Dr. Eyal Bressler & Co., Patent and Law Office, jointly with:
Dr. Eyal Bressler (PhD, Advocate & Patent Attorney), Founder of Dr. Eyal Bressler & Co., Patent and Law Office, “Medical Cannabis Franchising vs. IPR Licensing—Critical Do’s and Don’ts.” ■
